Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2019 Jun 17.
Published in final edited form as: J Biol Chem. 2006 Nov 22;282(4):2596–2605. doi: 10.1074/jbc.M609557200

Structural Characterization of the Active Site of the PduO-Type ATP:Co(I)rrinoid Adenosyltransferase from Lactobacillus reuteri

Martin St Maurice ‡,1,2, Paola E Mera §,1,3, María P Taranto ¶,4, Fernando Sesma ¶,4, Jorge C Escalante-Semerena §,5, Ivan Rayment ‡,6
PMCID: PMC6574208  NIHMSID: NIHMS1034792  PMID: 17121823

Abstract

The three-dimensional crystal structure of the PduO-type corrinoid adenosyltransferase from Lactobacillus reuteri (LrPduO) has been solved to 1.68-Å resolution. The functional assignment of LrPduO as a corrinoid adenosyltransferase was confirmed by in vivo and in vitro evidence. The enzyme has an apparent KmATP of 2.2 μM and KmCobalamin of 0.13 μM and a kcat of 0.025 s−1. Co-crystallization of the enzyme with Mg-ATP resulted in well-defined electron density for an N-terminal loop that had been disordered in other PduO-type enzyme structures. This newly defined N-terminal loop makes up the lower portion of the enzyme active site with the other half being contributed from an adjacent subunit. These results provide the first detailed description of the enzyme active site for a PduO-type adenosyltransferase and identify a unique ATP binding motif at the protein N terminus. The molecular architecture at the active site offers valuable new insight into the role of various residues responsible for the human disease methylmalonic aciduria.


B12 (cobalamin, Cbl)7 is an essential nutrient for animals, lower eukaryotes, and prokaryotes, but is synthesized exclusively by prokaryotes (1). Adenosylation of the corrinoid ring of Cbl generates coenzyme B12 (adenosylcobalamin, AdoCbl), an essential cofactor used by enzymes that catalyze intramolecular rearrangements (24), deaminations (5), dehydrations (6), reductions (7, 8), and reductive dehalogenations (9). Corrinoid adenosyltransferases play a key role in the biosynthesis of AdoCbl by covalently attaching the 5′-deoxyadenosyl moiety from ATP to the Co(I) ion of the corrin ring of Cbl (10, 11). These enzymes generate a biologically unique, labile cobalt-carbon bond that is the source of the unusual chemistry associated with the B12 cofactor. As such, understanding the mechanistic strategies of those enzymes involved in the formation of this carbon-metal bond is of considerable interest. In Salmonella enterica, three separate cob(I)alamin adenosyltransferases have been identified: CobA, PduO, and EutT. All cob(I)alamin adenosyltransferases identified to date belong to one of these three distinct families. CobA is the housekeeping enzyme of S. enterica and is involved in the anaerobic de novo synthesis of AdoCbl. The structure and function of this enzyme has been well characterized (1216). The PduO and EutT enzymes, meanwhile, assimilate existing Cbl into AdoCbl. Both PduO and EutT are encoded within large, discreet operons of S. enterica where they play specialized roles in the catabolism of 1,2-propanediol or ethanolamine (1719). Despite its specialized role in S. enterica, the PduO-type enzyme is the most widely distributed of these adenosyltransferases with homologues identified in species of archaeotes and prokaryotes, as well as in many eukaryotes, ranging from yeast to humans (19). In animals, PduO is the only cob(I)alamin adenosyltransferase enzyme available for the assimilation of dietary cobalamins into coenzyme B12.

Humans, who lack the ability to synthesize Cbl de novo, produce AdoCbl from reduced Cbl through a PduO-type adenosyltransferase (1921). Patients with malfunctions in this enzyme suffer from methylmalonic aciduria and metabolic ketoacidosis (22). Initial biochemical, functional, and structural characterization of PduO-type corrinoid adenosyltransferases has recently been reported, including a high-resolution three-dimensional crystal structure of the PduO-type enzyme from the archaeon Thermoplasma acidophilum (23), and two additional homologous structures deposited in the RCSB protein data bank (Bacillus subtilis YvqK, 1RTY; and a putative PduO from Mycobacterium tuberculosis, 2G2D). These structures reveal that the enzyme is a trimer with each subunit composed of a five helix-bundle. Unfortunately, the absence of bound substrates in these crystal structures has precluded identification of a definitive location for the active site. Whereas both the CobA- and PduO-type adenosyltransferases catalyze the elimination of tripolyphosphate from ATP (a relatively rare mechanism among the vast families of ATP-utilizing enzymes), theCobA-type adenosyltransferases utilize an inverted P-loop motif for ATP binding and elimination of tripolyphosphate while the PduO-type enzymes apparently lack such a motif (12, 24, 25). Currently, there is no clear structural or biochemical characterization of the ATP binding site in a PduO-type enzyme.

Recently, Lactobacillus reuteri strain CRL1098 was discovered to make B12 de novo (26), and a gene putatively encoding a homolog of the SePduO enzyme was identified among the cluster of B12 biosynthetic genes of this bacterium (GenBank™ accession number AY780645). In this study, we report the three-dimensional crystal structure of L. reuteri PduO-type corrinoid adenosyltransferase (LrPduO) complexed with MgATP at 1.68-Å resolution and provide a kinetic characterization of the enzyme. Despite limited sequence identity (31%), the LrPduO protein shares a common fold with the apo PduO protein from T. acidophilum (TaPduO). Our structure model reveals the active site in a deep cleft at the subunit interface made up, in part, of the immediate N terminus of the protein. A description of the active site unveils a previously unseen ATP binding motif and provides a framework for better understanding the various mechanistic strategies employed by cob(I)-alamin adenosyltransferase enzymes. Further, this description of ATP binding allows fresh insight into the molecular basis for protein malfunction in mutations of the human corrinoid adenosyltransferase.

EXPERIMENTAL PROCEDURES

Construction of Expression Vectors—

To generate an N-terminal (His)6-tagged recombinant construct of PduO, the L. reuteri pduO gene (GenBank™ accession number AY780645) was PCR-amplified from L. reuteri strain CRL1098 genomic DNA isolated as described (27). The primers used for amplification were 5′-CGGGATCCGTGAAGATTTATACAAAAAATGG-3′ (forward), and 5′-GGAATTCTTAGCGGAAAACGTCTTTACTGTT-3′ (reverse). The PCR fragment was restriction-digested with BamHI and EcoRI and ligated into the pET-28b vector (EMD Biosciences, Inc.) generating the expression plasmid pPDU19 (Table 1), which expresses the recombinant PduO protein with a 35-amino acid N-terminal tag. To generate a recombinant protein with a rTEV proteasecleavable N-terminal (His)6 tag, the L. reuteri pduO gene was PCR-amplified from plasmid pPDU19. The primers used for the amplification were 5′-AAAAAAACCATGGTGAAGATTTATACAAAAAATGGTGATAAAGGGC-3′ (forward) and 5′-TTTTTTGCGGCCGCTTAGCGGAAAAC-3′ (reverse). The PCR fragment was cut with NcoI and NotI and was ligated into vector pTEV3 (Table 1) yielding plasmid pPDU22. The pPDU22 vector directs the synthesis of a recombinant N-terminally tagged protein with the Tev protease site four residues upstream of the first amino acid of the LrPduO protein. The N-terminal amino acid sequence of this construct is MSYYHHHHHHDYDIPTSENLYFQGASAPM1V2 … where the location of the TEV protease cleavage site is underlined.

TABLE 1. Strains and plasmids.

Unless otherwise stated, strains were constructed during the course of these studies.

Genotype Source or Ref.
Plasmids
 pET-15b bla+ Novagen
 pCOBA17 pET15b cobAse+ bla+ Escalante-Semerena lab collection
 pPDU19 pET28b pduOLr+ kan+
 pTEV3 pET31b H6-tag, rTEV site at NdeI and Bpu1102I, MCS (NheI, NcoI EcoRI, XhoI, SacI, SmaI, BamHI, SacII, NotI, Bpu1102I) bla+ lacI+ Escalante-Semerena lab collection
 pPDU22 pTEV3 pduOLr+ bla+
Strains
E. coli
  (JE3892) BL21(λDE3) F dcm impT hsdS(rB mB) gal λ(DE3) New England Biolabs
S. entericaa
  TR6583 metE205 ara-9 cobA+ K. Sanderson via J. Roth
  JE1293 cobA366::Tn10d(cat+) Escalante-Semerena Laboratory Collection
  JE8740 cobA366::Tn10d(cat+)/pCOBA17 Escalante-Semerena Laboratory Collection
  JE8741 cobA366::Tn10d(cat+)/pPDU19 Escalante-Semerena Laboratory Collection
  JE8742 cobA366::Tn10d(cat+)/pET15b Escalante-Semerena Laboratory Collection
L. reuterib Wild-type strain CRL1098 26
a

Derivatives of S. enterica serovar Typhimurium strain LT2.

b

CERELA stock collection, B12 producer.

Strains, Media, and Chemicals—

Bacterial strains and plasmids used in this study are listed in Table 1. Chemicals were purchased from Sigma. Lysogenic broth (LB) (28, 29) was used as rich medium to propagate bacteria nonselectively. Vogel and Bonner’s no-carbon E (NCE) minimal medium (30, 31) was used to assess cobalamin biosynthesis. NCE medium was supplemented with glycerol (22 mM), MgSO4 (1 mM), dicyanocobinamide ((CN)2Cbi, 0.2 μM)), kanamycin (15μg/ml), or ampicillin (25μg/ml). Growth behavior was monitored at 650 nm using a Bio-Tek EL808 96-well platereader. Each well contained 198μl of fresh NCE medium that was inoculated with 2 μl of an overnight culture of the strain of interest grown in LB medium; each strain was analyzed in triplicate. Plates (Becton Dickinson) were incubated under aerobic conditions at 37 °C over a 24-h period.

LrPduO Protein Production and Purification—

Plasmids were transformed into Escherichia coli strain BL21(λDE3) for overexpression. Strains were grown at 37 °C with shaking in 1 liter of LB medium supplemented with kanamycin (25 μg/ml). After the culture reached an optical density (OD650) of 0.6 – 0.7, synthesis of the phage T7 RNA polymerase enzyme was induced by the addition of isopropyl-β-D-thiogalactopyranoside to a final concentration of 0.5 mM. Cells were grown for an additional 2 h at 37 °C with shaking, and harvested by centrifugation at 12,000 × g with a Beckman/Coulter Avanti J-25I centrifuge equipped with a JLA-16.250 rotor. The cell pellet was frozen at −80 °C until used. For protein purification, cell pellets were thawed and re-suspended in 20 ml of Tris-HCl buffer (0.1 M, pH 8.0 at 4 °C) containing the protease inhibitor phenylmethanesulfonyl fluoride (0.8 mM), imidazole (20 mM), and NaCl (0.5 M). Cells were broken using a French pressure cell (1.03 × 107 kPa); three passages ensured >99% breakage. Cell debris was separated from soluble proteins by centrifugation at 4 °C for 45 min at 45,000 × g. The resulting supernatant was filtered (0.45 μm; Nalgene), and proteins were resolved on a 5-ml HisTrap FF column (Amersham Biosciences). Proteins were desorbed from the column with a linear gradient of Tris-HCl buffer (0.1 M, pH 8.0 at 4 °C) containing imidazole (0.5 M) and NaCl (0.5 M); 2-ml fractions were collected. Initial estimates of protein purity were made by SDS-PAGE (32) and Coomassie Blue staining (33). Fractions containing LrPduO protein of the highest purity were pooled and sequentially dialyzed at 4 °C against buffer A (Tris-HCl (0.1 M, pH 8 at 4 °C) containing NaCl (0.5 M), EDTA, 2 mM), buffer B (buffer A lacking EDTA), and buffer C (Tris-HCl (10 mM, pH 8 at 4 °C) containing NaCl (0.3 M) and Mg-ATP (3 mM)). Final protein purity was assessed with Fotodyne’s FOTO/Eclipse® Electronic Documentation & Analysis System, including software packages FOTO/Analyst® PC Image v5.0 and TotalLabTM one-dimensional gel analysis v2003 from NonLinear Dynamics, Ltd. Purified LrPduO protein was estimated to be >99% homogeneous and gave a yield of 40 mg from 1 liter of broth culture. This highly purified LrPduO protein was flash-frozen in liquid nitrogen in 40-μl droplets and stored at −80 °C until used. LrPduO protein with a TEV cleavable, N-terminal poly-His tag was overproduced from plasmid pPDU22 and initially purified as described above. Prior to dialysis, purified rTEV protease (3436) was mixed with LrPduO in a 1:50 rTEV:LrPduO molar ratio, and incubated at room temperature for 3 h. The mixture was dialyzed overnight against buffer D (buffer A containing imidazole, 10 mM), followed by a 4-h dialysis at 4 °C against buffer E (Tris-HCl, 0.1 M, pH 8 at 4 °C containing NaCl, 0.5 M, and imidazole, 10 mM). The rTEV:LrPduO protein mixture was loaded onto a 5-ml HisTrap FF column. The column flow-through was collected and dialyzed against Tris-HCl buffer (0.1 M, pH8.0 at 4 °C) containing NaCl (0.5 M) and 10% (v/v) glycerol. Tag-less LrPduO used for kinetic analysis was stored at −80 °C until used.

In Vitro Adenosyltransferase Activity Assay—

Activity assays were performed as described (37) with the following modifications. The final volume of each reaction was 1 ml. Empty, sealed quartz cuvettes were flushed with oxygen-free N2 for 5 min. Under a stream of O2-free N2, Tris-HCl (0.2 M; pH 8.0 at 37 °C), hydroxocobalamin (HOCbl 0.1–10 μM), MgCl2 (0.5 mM), ATP (1 μM-1 mM), and Ti(III)citrate (0.1 mM) were added to the cuvette in the order stated. After all additions were made, flushing was continued for 30 s. To ensure that all Co(III) was reduced to Co(I), reaction mixtures were incubated at 37 °C for 5 min. The adenosylation reaction was initiated by the addition of LrPduO protein (45 nM). Adenosylcobalamin (AdoCbl) formation was monitored at 388 nm.

Crystallization and Data Collection—

Crystals of the recombinant native protein, expressed with a 35-amino acid, N-terminal-(His)6 tag, were grown at 20 °C in hanging drop by mixing 4 μl of 20 mg/ml protein in buffer C with 4 μl of precipitant solution composed of HEPPS (0.1 M, pH 8.5), ammonium sulfate (1.9 M, pH 8.5), MgCl2 (0.1 M), and HOCbl (4 mM). The resulting solution was microseeded after 24 h, resulting in the growth of cubic-shaped, pink crystals (~300 μm3) within 3–5 days. Crystals were transferred to a synthetic mother liquor solution containing HEPPS, (0.11 M, pH 8.5), ammonium sulfate (1.1 M, pH 8.5), ATP (2 mM), MgCl2 (55 mM), NaCl (165 mM), and HOCbl (15 mM) and allowed to soak for 7 days. The coloration of the crystals darkened from pink to red over the course of the soak. The soaked crystals were incrementally transferred in five steps to a cryoprotectant solution consisting of HEPPS (0.11 M, pH 8.5), ammonium sulfate (1.2 M, pH 8.5), ATP (3 mM), MgCl2 (55 mM), NaCl (0.3 M), HOCbl (15 mM), and glycerol (20% v/v) and were flash cooled in a nitrogen stream at 100 K (Oxford Cryosystems, Oxford, UK). The crystals belonged to the space group I23, with one subunit in the asymmetric unit and the unit cell parameters a = b = c = 110.6 Å. A dataset was collected at the SBC 19BM beamline of Advanced Photon Source in Argonne, IL. Diffraction data were integrated and scaled with the program HKL2000 (38). Data collection are summarized in Table 2.

TABLE 2.

X-ray data collection and refinement statistics

Space group I23
Unit-cell parameters (Å) a = b = c = 110.6
Resolution range (Å) 50.00–1.68
Reflections: measured 243 527
Reflections: unique 25 595
Redundancy 9.5 (6.8)a
Completeness (%) 99.5 (99.5)
Average I/σ 43.1 (4.1)
Rsym (%) 4.6 (23.4)
Rwork (%) 17.3 (21.5)
Rfree (%) 20.4 (25.2)
No. protein atoms 1521
No. water molecules 141
Wilson B-value (Å2) 22.0
Average B factors (Å2)
 PduO 23.0
 Mg-ATP 15.7
 Solvent 37.4
Ramachandran (%)
 Most favored 96.9
 Additionally allowed 2.5
 Generously allowed 0
 Disallowed 0.6b
r.m.s. deviations
 Bond lengths (Å) 0.011
 Bond angles (°) 1.35
a

Values in parentheses are for the highest resolution bin (1.74–1.68 Å resolution).

b

Lys110 lies in an external loop region of high disorder.

Structure Determination and Refinement—

The structure was determined by molecular replacement with the program MOLREP (39) starting from the model for TA1434, a PduO-type cob(I)alamin adenosyltransferase from T. acidophilum (PDB accession identifier 1NOG, Ref. 23), for which there is 31% identity with the protein sequence of LrPduO. Residues 3–181 for the L. reuteri enzyme were built automatically into the electron density by the program ARP/WARP (40), and the structure was refined with the program REFMAC (41). The initial structure was subject to manual verification. Multiple conformations were added with the program COOT (42). Water molecules were added to the dataset by ARP/WARP with subsequent manual verification. The final model, refined to 1.68-Å resolution, includes residues Lys2–Asn182 of LrPduO and the heteroatom Mg-ATP with the following 15 residues displaying multiple conformations: Gln19, Lys45, Ile48, Val54, Ser56, Glu60, Phe67, Ser83, Gln90, Val105, Ala108, Arg128, Arg132, Gln140, Met178. Residues Met1 and Ser183-Arg188, and those residues corresponding to the preceding 35 amino acids of the N-terminal tag were disordered and were not built into the model. The side chains corresponding to Arg14, Glu60, Lys85, Gln104, Lys110, Lys111, Gln146, Arg181, Asn182 were disordered and could not be built into the electron density map. Despite the mild red coloration of crystals grown and soaked in the presence of HOCbl, no electron density was observed in the map that could be attributed to fully occupied HOCbl. All figures of molecular structures were generated with the program PyMOL. A Ramachandran plot shows that 96.9% of the residues are in the most favored region, with one outlier that lies in a flexible loop. Refinement statistics are summarized in Table 2.

RESULTS AND DISCUSSION

The LrPduO Protein Has ATP:Co(I)rrinoid Adenosyltransferase Enzyme Activity—

Results from complementation studies involving LrPduO protein are shown in Fig. 1. The growth defect of a strain of S. enterica lacking the housekeeping ATP: co(I)rrinoid adenosyltransferase (CobA) enzyme was corrected by the presence of a plasmid encoding the LrPduO protein (Fig. 1, closed versus open triangles). Under the growth conditions used in this study, S. enterica does not express endogenous PduO, nor does it express eutT (44,45). Therefore, the conditions of the above-mentioned experiments demanded that the LrPduO protein adenosylate cobinamide prior to its conversion to AdoCbl (46). Hence, on the basis of these data, it is concluded that LrPduO is involved in corrinoid adenosylation. Given the homology of LrPduO to the N-terminal domain of S. enterica PduO (SePduO; Fig. 2), it was hypothesized that the LrPduO protein catalyzes the formation of the unique Co-C bond between the 5′-deoxyadenosyl moiety of ATP and the cobalt ion of the corrin ring.

FIGURE 1. LrPduO compensates for the lack of CobA enzyme.

FIGURE 1.

All strains used in these studies carried a null allele of the metE gene (encodes the B12- independent methionine synthase) and a deletion of the cobA gene in their chromosome. Cells were grown in NCE minimal medium as described under “Experimental Procedures.” The growth conditions used for this analysis demanded adenosylation of the precursor cobinamide prior to its conversion to AdoCbl. The following growth rates (ΔOD650 h−1) were calculated for each strain using the GraphPad Prism® v4 software package: cobA+(closed circles),0.15 + 0.11; cobA/pET-15b (open triangles, empty vector control), 0.001; cobA/pSecobA+(open circles, positive control), 0.11 + 0.006; cobA/pLrpduO+(closed triangles, experiment), 0.105 + 0.009.

FIGURE 2. Multiple protein sequence alignment for PduO-type adenosyltransferase enzymes.

FIGURE 2.

Alignments were generated using T-Coffee (55). All aligned sequences are from confirmed structural and/or functional homologues of PduO. The sequences for both Homo sapiens and B. taurus are shown without the predicted N-terminal mitochondrion-targeting sequence and only the N-terminal domain of the S. enterica sequence is shown. The numbering corresponds to the sequence for the L. reuteri enzyme. The residues shaded in black are universally conserved while the boxed residues are strongly conserved. Residues indicated with a star are implicated in ATP binding at the active site. The GenBank™ accession numbers for each sequence are listed in parentheses.

Kinetics of the Reaction Catalyzed by LrPduO—

Direct evidence that LrPduO catalyzes the last step of the corrinoid adenosylation pathway (13) was obtained in vitro. Initial velocity kinetic determinations were performed using chemically reduced cob(I)alamin and ATP as substrates for purified LrPduO protein that did or did not have an N-terminal tag. Kinetic constants were measured by holding one substrate at saturation while the other was varied (Table 3). These data confirmed that the LrPduO protein has ATP:cob(I)alamin adenosyltransferase enzyme activity. The apparent Km for ATP (Km, 2 μM) at saturating cob(I)alamin is similar to the one reported for the human PduO- type adenosyltransferase (Km, 6 μM) (20, 47), but is lower than that reported for the PduO enzymes from T. acidophilum (Km, 110 μM) (23) and S. enterica (Km, 20 μM) (48). Notably, the apparent Km for cob(I)alamin at saturating ATP is at least 10-fold lower than any previously reported Km value for any type of ATP:adenosyltransferase (Km, 1–5 μM). The apparent kcat for the L. reuteri enzyme (0.03 s−1) is also lower than what has been reported for other adenosyltransferases (kcat = 0.1–0.3 s−1), bringing the kcat/Km values for the L. reuteri enzyme within the range of what has been reported for the other enzymes (kcat/Km = 104 −105 M−1 s−1 Our results indicate that the presence of the 35-residue N-terminal tag has only a small effect on the reaction kinetics. Similar kinetic results have been reported for the N-terminal GST-tagged construct of hATR (47) and the mitochondrial targeting sequence-tagged bovine PduO (19). Based on the location of the active site at the immediate N terminus of LrPduO (see the structural description below), the slightly elevated Km values for the tagged enzyme may reflect a minor impedance of access to the active site with a concomitant reduction in the overall binding affinity.

TABLE 3.

Kinetic parameters for native and N-terminally tagged LrPduO

Substrate varied N-terminally tagged LrPduO Untagged LrPduO (NH2–GSASPM1V2K3…)
Km kcat kcat/Km Km kcat kcat/Km
μM S−1 M−1S−1 μM S−1 M−1S−1
HOCbl 0.31 ± 0.05 2.8 ± 0.2 × 10−2 9.0 ± 1.6 × 104 0.13 ± 0.01 2.4 ± 0.1 × 10−2 1.8 ± 0.2 × 105
ATP 3.3 ± 0.8 2.8 ± 0.1 × 10−2 8.5 ± 2.1 × 103 2.2 ± 0.1 2.6 ± 0.1 × 10−2 1.2 ± 0.1 × 104

Overall Structure and Description of the Active Site—

The structure of LrPduO was determined for the N-terminally tagged protein using molecular replacement, with initial phases from the crystal structure of TA1434 (PDB accession identifier 1NOG), a PduO-type ATP:cob(I)alamin adenosyltransferase from T. acidophilum crystallized in the absence of ligands (23), with which LrPduO shares 31% sequence identity. The structure was solved for the tagged version of the enzyme, as this particular construct crystallized more readily than did the construct with the proteolytically removed tag. The final structure was refined to 1.68-Å resolution, with an Rwork of 17.3 and an Rfree of 20.4. As with the enzyme from T. acidophilum, LrPduO is a trimer consisting of three independent five-helix bundles with an overall topology of 12354 (Fig. 3). The interactions between the individual helices and subunits are similar to those described for the T. acidophilum enzyme (23). Notably, while the immediate N terminus of all previously reported structures of PduO-type adenosyltransferases has been disordered, the structure of LrPduO is unique in that it includes an additional ordered 23 amino acids at the immediate N terminus of the protein (Fig. 4). The newly defined structure of the N terminus spans residues 2–24 of the native polypeptide chain and does not include any contributions from the 35-residue N-terminal tag. Aside from this ordered N-terminal loop, no significant conformational changes accompany ATP binding, with low r.m.s. deviations (0.6–1.3 Å) for the superposition of the LrPduO structure with three structures of the apoenzyme. The N terminus is well-ordered (average B-value, 23.4) and consists of a region of random coil with a helical twist followed by two antiparallel β-strands interspaced by a loop of five residues. Electron density is clearly observable for Mg-ATP within this N-terminal cleft with the positions and orientations of the phosphates and the nucleotide ring very well defined (Fig. 5a). The N terminus accounts for the lower half of the enzyme active site with additional residues being contributed from helix four and five of the neighboring subunit. Unlike the inverted P-loop observed for CobA (12), the ATP binding site of LrPduO does not conform to any of the classic nucleotide binding structural motifs as seen in the ATP grasp or protein kinase families. The N-terminal ATP-binding loop is made up of several highly conserved residues and is clamped into position through a salt bridge between two conserved residues: Asp9 of the N-terminal loop and Arg157 from helix five of the neighboring subunit. The overall backbone structure of this loop is kept rigid through a pair of backbone hydrogen bonds (Lys6–Asp9; Gly8–Gly11) that preserve a tight helical twist leading into the first β-strand. Both Gly8 and Gly11 are conserved among homologs of SePduO, further suggesting a key role in scaffolding the structure of the ATP binding loop. It appears that MgATP binding is responsible for ordering the N-terminal loop. Unfortunately, despite co-crystallization with HOCbl, only small lobes of difference electron density were observed in the vicinity of the active site, indicating low occupancy for this ligand. The binding region for HOCbl, therefore, could not be modeled with confidence. However, identification of the binding site for MgATP does place restraints on the binding site for HOCbl.

FIGURE 3. Ribbon representations of ATP-bound LrPduO.

FIGURE 3.

a, stereoview of a single subunit of LrPduO colored in rainbow format, beginning with blue at the N terminus and ending in red at the C terminus. A stick representation showing the position of Mg-ATP at the N-terminal binding site is also labeled. b, stereoview of the trimeric enzyme with the 3-fold axis of symmetry indicated. A space-filling representation denotes the positions of Mg-ATP.

FIGURE 4. Structural overlay of PduO-type adenosyltransferase enzymes.

FIGURE 4.

Stereoview of the α-carbon backbone of B. subtilis YvqK (1RTY), T. acidophilum PduO (1NOG), and the putative PduO from M. tuberculosis (2G2D) aligned with the α-carbon backbone of LrPduO (shown in red) using the program ALIGN (55). The r.m.s. deviations for alignments excluding the N-terminal 23 residues of LrPduO were 0.63, 1.10, and 1.26 Å with the enzymes from B. subtilis, T. acidophilum, and M. tuberculosis, respectively.

FIGURE 5. Mg-ATP in the LrPduO active site.

FIGURE 5.

a, stereoview of the representative electron density corresponding to Mg-ATP. The FoFc electron density omit map for Mg-ATP was contoured at 3.0 σ. b, stereoview of the active site of LrPduO depicting the residues interacting with Mg-ATP. c, schematic representation of the interactions made by LrPduO with Mg-ATP. Hydrogen bonding interactions and distances in Å are indicated. This figure was produced with the program ligplot (56). For clarity, Arg132 is represented in the conformation where its occupancy is the highest (~0.75) while Arg128 is represented in one of its two equivalent conformations.

ATP Binding at the Active Site of LrPduO—

Mg-ATP is bound through direct interactions with 9 residues contributed from adjacent subunits of the trimer (Fig. 5, b and c). A total of 6 residues whose side chains are directly involved in binding are conserved among PduO-type adenosyltransferase enzymes (Fig. 2). This includes the hydroxyl of Thr13, which appears to be structurally conserved as either a serine or threonine. The majority of enzyme-substrate interactions are centered on the tripolyphosphate of ATP. As such, these interactions are expected to contribute significantly to ordering the N-terminal loop upon ATP binding. Several of these interactions originate from main chain amide hydrogens and carbonyls on the N-terminal loop, lending importance to the conservation of Gly8 and Gly11 in maintaining the overall fold. The phosphate oxygen atoms of the enzyme-bound ATP are positioned to provide 3 coordination bonds to Mg2+. In addition, two highly ordered water molecules along with the carbonyl oxygen of Asn156 provide the remaining coordination to the bipyramidal Mg2+. Whereas many interactions with the triphosphate of ATP originate from a conserved sequence motif at the N terminus, this sequence motif appears to be unique to this class of enzymes, despite its high sequence conservation among the PduO-type adenosyltransferases(Fig.2). Asearch of the protein data base using the conserved sequence Thr-(Lys/Arg)-X-Gly-Asp-X-Gly-X-(Thr/Ser), corresponding to residues 5–13 of the LrPduO phosphate binding domain, revealed no significant similarities with existing protein classes. Whereas the conserved amino acid sequence of PduO loosely shares features of the consensus tripolyphosphate binding sequence of the mechanistically similar adenosylmethionine synthetase and inorganic pyrophosphatase (49), a structural comparison with the active site of adenosylmethionine synthetase(50) reveals no striking similarities in the overall fold responsible for ATP binding. PduO catalyzes the elimination of tripolyphosphate from ATP (14, 48), a relatively uncommon mechanism among ATP-utilizing enzymes.

The conserved residue Arg132 is poised to play a critical role in stabilizing developing negative charge in the transition state and also in properly orienting the C5′-carbon of ATP for nucleophilic attack through two hydrogen bonding contacts with the bridging oxygen of ribose (2.7 Å) and the bridging oxygen to the α-phosphate (2.4 Å). Whereas the precise nature of its catalytic role awaits detailed mutagenic analysis, it is noteworthy that an Arg to His mutation of the structurally equivalent residue in hATR results in a complete loss of enzyme activity (47). Interestingly, CobA has no comparable protein-ligand contacts centered around the C-5′ carbon, reinforcing the notion that the PduO- and CobA-type adenosyltransferase enzymes are mechanistically distinct despite their common overall reactions and similar efficiencies. Arg132, along with the neighboring residue, Arg128, displays alternate conformations in the crystal structure. In the absence of HOCbl it is difficult to assess which set of conformations is mechanistically important.

In addition to the contact between the Arg132 side chain and the bridging ribose, Glu135 and the main chain carbonyl oxygens of Arg132 and Arg14 are the only apparent bonding interactions between the protein and the adenosine base. Of these, only the side chain of Glu135 contacts the C-6 amine that is specific to adenine. This small number of contacts may facilitate the transfer of adenosine to cobalamin and the subsequent leaving of the first product, AdoCbl. This lack of a stringent set of binding contacts combined with a lack of tight packing around the base moiety also suggests an active site with sufficient conformational freedom to accommodate nucleotides other than ATP. While CobA type adenosyltransferases have long been known to accommodate alternate nucleotides (10, 14, 25, 51), the TaPduO and SePduO accept only ATP (23, 48). However, the human PduO enzyme does display moderate catalytic activity with several alternate nucleotides (19).

A survey of LrPduO relative specific activities for a series of alternate nucleotides revealed specificity for a broad set of nucleotides (Table 4) with relative efficiencies similar to those described for hATR. While a detailed structural interpretation of the relative observed rates requires further kinetic analysis, it is interesting to note the low specific activity of ITP compared with ATP. The difference between these two nucleotides is limited to the identity of the functional group at the C-6 position of the purine base. Substitution at C-6 of the hydrogen bond-donating amine of ATP for the hydrogen bond-accepting carbonyl of ITP results in a 100- fold reduction in specific activity. Provided that this reduction in activity results primarily from a loss of binding affinity, the reduced specific activity with ITP may be attributed to the loss of a critical hydrogen bonding interaction with the backbone carbonyl of Arg132. GTP, which also has a carbonyl at C-6, may recover a portion of this lost binding energy through a favorable potential hydrogen bonding interaction between its C-2 amine and the backbone carbonyl of Val28. It is, however, more difficult to structurally interpret the reduced specific activities observed for CTP and UTP on account of the smaller relative size of the purine bases.

TABLE 4.

Relative specific activities of LrPduO for alternate nucleotides

Nucleotide substrate Relative activity
1 mM 10 μM HOCbl
ATP 100 ± 2%
2′-deoxy-ATP 13 ± 1%
ADP 6.6 ± 0.4%
AMP None detected
GTP 36 ± 4%
CTP 1.4 ± 0.1%
ITP 0.8 ± 0.2%
UTP None detected

A subset of PduO-type enzymes is now emerging that can be defined by the ability of the enzyme to accept alternate nucleotides in place of ATP. In addition, the Km of LrPduO for ATP (3 μM) is closer to that reported for the human enzyme (7 μM) than it is to those values reported for the SePduO (18 μM) or TaPduO (110 μM) enzymes. Interestingly, neither humans nor lactobacilli have an identified CobA homolog, leaving the PduO-type adenosyltransferase as the only enzyme available for the conversion of Cbl to coenzyme B12. In contrast, the genome of T. acidophilum does contain a gene encoding a putative CobA homolog (30% identical to SeCobA). Whether the presence of a CobA-type enzyme has an effect on the specificity and efficiency of PduO enzymes remains an open question.

The Putative Corrinoid Binding Site—

The crystal structure of LrPduO, like that of CobA (12), reveals ATP bound in a deep cleft at the active site. In CobA, the C-5′ carbon of ribose is positioned such that it is poised for nucleophilic attack by the reduced cobalt atom bound above. A similar scenario would be expected for the binding of cob(I)alamin in PduO. However, despite the high apparent binding affinity of cob(I)alamin for the enzyme at saturating concentrations of ATP, attempts to co-crystallize the enzyme in the presence of 2 mM HOCbl and to soak the crystals in 15 mM HOCbl did not result in any interpretable electron density for this substrate in the final structure. The crystals gained a mild red coloration when co-crystallized with HOCbl and subsequently gained a deeper red coloration upon soaking, indicating some degree of binding. Whereas HOCbl is expected to have a lower affinity than reduced cob(I)alamin, its dissociation constant for the human enzyme has been measured fluorimetrically as ~9 μM (52). It is likely that the high concentration of ammonium sulfate in the crystallization solutions significantly reduces the overall binding affinity of HOCbl for the enzyme. Attempts to co-crystallize the TaPduO enzyme with cobalamin have also been unsuccessful(23). Nevertheless, it is likely that the corrinoid substrate is bound immediately adjacent to ATP in a large surface-exposed hole (Fig. 6). PduO catalyzes the direct transfer of the adenosyl moiety from ATP to reduced cobalamin, without proceeding through an enzyme-bound adenosylated intermediate (48). For such a direct transfer to take place, the corrinoid must be bound in close proximity to ATP. The hole immediately adjacent to ATP is large enough to accommodate the corrinoid but the orientation of the tetrapyrrole ring cannot be predicted because side chains lining the pocket will adopt different conformations on binding. Indeed, some lobes of electron density were interspersed throughout this hole at a signal level significantly exceeding background noise (σ > 3) and several residues lining this cavity (Asn19, Phe67, Ser83, Ala108, Arg128, Arg132) display alternate conformations. Furthermore, this cavity encompasses a localized area of positive electrostatic potential which may serve either to assist in binding the corrinoid substrate negatively charged phosphate moiety and/or to promote docking of the putative reductase that is responsible for reducing bound cob(II)alamin to cob(I)alamin (20).

FIGURE 6. Electrostatic surface potential stereoview for LrPduO centered on the putative cobalamin binding pocket.

FIGURE 6.

The electrostatic potential ranges from −20 kT (red) to +10 kT (blue). A space-filling representation of Mg-ATP is colored in green. The electrostatic potential was generated with the program APBS (57) using a protein dielectric constant of 2 and a solvent dielectric constant of 80.

Mechanistic Insights into Methylmalonic Aciduria—

The kinetic and structural characterization of the PduO-type enzyme from L. reuteri provides insights into the recent description of mutations in hATR responsible for methylmalonic aciduria (23, 47, 53, 54). Even though the sequence similarity between the human enzyme and LrPduO enzyme is only 39%, the similar kinetic constants and nucleotide specificity provide a structural framework for understanding the biochemical consequences of the mutations. Importantly, the majority of disease-related mutations are clustered around residues contributed from helix 5 to the active site (Fig. 7). Interestingly no mutations have been identified within the phosphate binding region on the N-terminal loop.

FIGURE 7. Map of mutations identified in patients belonging to the cblB complementation class of methylmalonic aciduria.

FIGURE 7.

The trimeric enzyme is illustrated with the human disease-related amino acid mutations (54) represented in a yellow space-filling representation at their equivalent position in the LrPduO enzyme. For clarity, relevant amino acid mutations are shown only for the monomer highlighted in orange. Mutations in hATR at residues Ser174, Arg186, Arg190, Arg191, Glu193, and Tyr219 are labeled and correspond to residues Gly116, Arg128, Arg132, Arg133, Glu135, and Tyr161, respectively in LrPduO. The majority of mutations are clustered near the binding site for Mg-ATP. ATP is illustrated in a stick representation.

The R186W mutation of hATR is particularly common in patients, accounting for ~30% of sequenced alleles and is associated with early onset of methylmalonic aciduria(54). Purification and characterization of the mutant enzymes R186W and R186A in vitro has been shown to result in a complete loss of activity (23, 47). The structurally equivalent residue of the LrPduO enzyme is Arg128.8 Whereas this residue does not directly interact with ATP, it is expected to play a critical role in catalysis as evidenced by its absolute conservation among PduO-type adenosyltransferases and the complete loss of enzyme activity that results from mutations at this position. There are several possible roles for Arg128. 1) Its location in the corrinoid binding pocket results in an important specific interaction with the corrin ring. Efforts to co-crystallize LrPduO with various corrinoid substrates are continuing to better define the interactions between the enzyme and the corrinoid substrate. 2) It interacts directly to properly position or stabilize Arg132 for catalysis, or 3) it forms a critical subunit-subunit contact through a salt bridge with the absolutely conserved Asp35 on the adjacent subunit. On this note, it is interesting that in hATR the R186W mutation results in apparently unstable protein in vivo (47), suggesting that a stabilizing subunit-subunit contact is lost in these mutant enzymes.

Both R190C and R190H have been identified in patients with methylmalonic aciduria (54). This residue is structurally equivalent to Arg132 in the LrPduO enzyme and is expected to be essential to catalysis as discussed above. It is also now clear that the E193K mutation found in patients with methylmalonic aciduria (equivalent to Glu135 in LrPduO) will result in the loss of a specific interaction with ATP in the active site and in the loss of a critical secondary residue responsible for positioning one of two Mg2+-coordinating water molecules in the active site.

The structure of LrPduO presented here answers many of the questions of how nucleotides bind to this class of adenosyltransferase, but other questions remain. In particular, knowledge of how the corrinoid binds in the active site is required to establish a molecular mechanism for adenosyltransfer and the role of conserved residues. The current study establishes the foundation for these future investigations.

Acknowledgments—

Use of the Structural Biology BM19 beamline Argonne National Laboratory Advanced Photon Source was supported by the United States Dept. of Energy, Office of Energy Research, under Contract No. W-31–109-ENG-38.

This work was supported in part by Grants AR35186 (to I. R.) and GM40313 (to J. C. E.-S.) from the National Institutes of Health. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Glossary

Cbl

cobalamin

LrPduO

L. reuteri PduO

TaPduO

T. acidophilum PduO

SePduO

S. enterica PduO

HEPPS

3-[4-(2-hydroxyethyl)-1-piperazinyl]propanesulfonic acid

AdoCbl

adenosylcobalamin

HOCbl

hydroxocobalamin

hATR

human adenosyltransferase

r.m.s.

root mean-squared

GST

glutathione S-transferase

Pa

Pascal

Footnotes

The atomic coordinates and structure factors (code2NT8) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).

8

Arg128 has two conformations in the LrPduO structure. Each conformation has independently been observed in other deposited structures of PduO. In one conformation, Arg128 forms an ideal salt bridge with Asp35 (this single conformation has also been observed in the coordinates 2G2D and 1RTY, for putative PduOs from M. tuberculosis and B. subtilis, respectively) whereas in the alternate conformation, the guanidinium functional group is shifted to position a nitrogen directly above the guanidinium group of Arg132. (This equivalent position was observed in the coordinates 1NOG for the T. acidophilum enzyme.)

REFERENCES

  • 1.Warren MJ, Raux E, Schubert HL, and Escalante-Semerena JC (2002) Nat. Prod. Rep 19, 390–412 [DOI] [PubMed] [Google Scholar]
  • 2.Halpern J (1985) Science 227, 869–875 [DOI] [PubMed] [Google Scholar]
  • 3.Buckel W, Bröker G, Bothe H, and Pierik A (1999) in Chemistry and Biochemistry of B12 (Banerjee R, ed) pp. 757–781, John Wiley & Sons, Inc., New York [Google Scholar]
  • 4.Banerjee R, and Chowdhury S (1999) in Chemistry and Biochemistry of B12 (Banerjee R, ed) pp. 707–729, John Wiley & Sons, Inc., New York [Google Scholar]
  • 5.Bandarian V, and Reed GH (1999) in Chemistry ad Biochemistry of B12 (Banerjee R, ed) pp. 811–833, John Wiley & Sons, Inc., New York [Google Scholar]
  • 6.Toraya T (1999) in Chemistry and Biochemistry of B12 (Banerjee R, ed) pp. 783–809, John Wiley & Sons, Inc., New York [Google Scholar]
  • 7.Fontecave M (1998) Cell. Mol. Life Sci. 54, 684–695 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Fontecave M, and Mulliez E (1999) in Chemistry and Biochemistry of B12 (Banerjee R, ed) pp. 731–756, John Wiley & Sons, Inc., New York [Google Scholar]
  • 9.Wohlfarth G, and Diekert G (1999) in Chemistry and Biochemistry of B12 (Banerjee R, ed) pp. 871–893, John Wiley & Sons, Inc., New York [Google Scholar]
  • 10.Vitols E, Walker GA, and Huennekens FM (1966) J. Biol. Chem 241, 1455–1461 [PubMed] [Google Scholar]
  • 11.Huennekens FM, Vitols KS, Fujii K, and Jacobsen DW (1982) in B12 (Dolphin D, ed) Vol. 1, pp. 145–168, John Wiley & Sons, Inc., New York [Google Scholar]
  • 12.Bauer CB, Fonseca MV, Holden HM, Thoden JB, Thompson TB, Escalante-Semerena JC, and Rayment I (2001) Biochemistry 40, 361–374 [DOI] [PubMed] [Google Scholar]
  • 13.Fonseca MV, and Escalante-Semerena JC (2001) J. Biol. Chem 276, 32101–32108 [DOI] [PubMed] [Google Scholar]
  • 14.Fonseca MV, Buan NR, Horswill AR, Rayment I, and Escalante-Semerena JC (2002) J. Biol. Chem 277, 33127–33131 [DOI] [PubMed] [Google Scholar]
  • 15.Stich TA, Buan NR, Escalante-Semerena JC, and Brunold TC (2005) J. Am. Chem. Soc 127, 8710–8719 [DOI] [PubMed] [Google Scholar]
  • 16.Buan NR, and Escalante-Semerena JC (2005) J. Biol. Chem 280, 40948–40956 [DOI] [PubMed] [Google Scholar]
  • 17.Buan NR, Suh SJ, and Escalante-Semerena JC (2004) J. Bacteriol 186, 5708–5714 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Buan NR, and Escalante-Semerena JC (2006) J. Biol. Chem 281, 16971–16977 [DOI] [PubMed] [Google Scholar]
  • 19.Leal NA, Park SD, Kima PE, and Bobik TA (2003) J. Biol. Chem 278, 9227–9234 [DOI] [PubMed] [Google Scholar]
  • 20.Leal NA, Olteanu H, Banerjee R, and Bobik TA (2004) J. Biol. Chem 279, 47536–47542 [DOI] [PubMed] [Google Scholar]
  • 21.Stich TA, Yamanishi M, Banerjee R, and Brunold TC (2005) J. Am. Chem. Soc 127, 7660–7661 [DOI] [PubMed] [Google Scholar]
  • 22.Ciani F, Donati MA, Tulli G, Poggi GM, Pasquini E, Rosenblatt DS, and Zammarchi E (2000) Crit. Care Med. 28, 2119–2121 [DOI] [PubMed] [Google Scholar]
  • 23.Saridakis V, Yakunin A, Xu X, Anandakumar P, Pennycooke M, Gu J, Cheung F, Lew JM, Sanishvili R, Joachimiak A, Arrowsmith CH, Christendat D, and Edwards AM (2004) J. Biol. Chem 279, 23646–23653 [DOI] [PubMed] [Google Scholar]
  • 24.Smith CA, and Rayment I (1996) Biophys. J 70, 1590–1602 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Buan NR, Rehfeld K, and Escalante-Semerena JC (2006) J. Bacteriol 188, 3543–3550 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Taranto MP, Vera JL, Hugenholtz J, De Valdez GF, and Sesma F (2003) J. Bacteriol 185, 5643–5647 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Pospiech A, and Neumann B (1995) Trends Genet. 11, 217–218 [DOI] [PubMed] [Google Scholar]
  • 28.Bertani G (1951) J. Bacteriol 62, 293–300 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Bertani G (2004) J. Bacteriol 186, 595–600 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Vogel HJ, and Bonner DM (1956) J. Biol. Chem 218, 97–106 [PubMed] [Google Scholar]
  • 31.Berkowitz D, Hushon JM, Whitfield HJ, Roth J, and Ames BN (1968) J. Bacteriol 96, 215–220 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Laemmli UK (1970) Nature 227, 680–685 [DOI] [PubMed] [Google Scholar]
  • 33.Sasse J (1991) in Current Protocols in Molecular Biology (Ausubel FA, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, and Struhl K, eds) Vol. 1, pp. 10.6.1–10.6.8, Wiley Interscience, New York [Google Scholar]
  • 34.Haspel J, Blanco C, Jacob J, and Grumet M (2001) BioTechniques 30, 60–61, 64–66 [DOI] [PubMed] [Google Scholar]
  • 35.Kapust RB, and Waugh DS (2000) Protein Expr. Purif 19, 312–318 [DOI] [PubMed] [Google Scholar]
  • 36.Shih YP, Wu HC, Hu SM, Wang TF, and Wang AH (2005) Protein Sci. 14, 936–941 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Johnson CL, Pechonick E, Park SD, Havemann GD, Leal NA, and Bobik TA (2001) J. Bacteriol 183, 1577–1584 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Otwinowski Z, and Minor W (1997) Methods Enzymol. 276, 307–326 [DOI] [PubMed] [Google Scholar]
  • 39.Vagin A, and Teplyakov A (1997) J. Appl. Crystallogr 30, 1022–1025 [Google Scholar]
  • 40.Perrakis A, Harkiolaki M, Wilson KS, and Lamzin VS (2001) Acta Crystallogr. D Biol. Crystallogr 57, 1445–1450 [DOI] [PubMed] [Google Scholar]
  • 41.Murshudov GN, Vagin AA, and Dodson EJ (1997) Acta Crystallogr. D Biol. Crystallogr 53, 240–255 [DOI] [PubMed] [Google Scholar]
  • 42.Emsley P, and Cowtan K (2004) Acta Crystallogr. D Biol. Crystallogr 60, 2126–2132 [DOI] [PubMed] [Google Scholar]
  • 43. Deleted in proof.
  • 44.Ailion M, Bobik TA, and Roth JR (1993) J. Bacteriol 175, 7200–7208 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Sheppard DE, and Roth JR (1994) J. Bacteriol 176, 1287–1296 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Escalante-Semerena JC, Suh SJ, and Roth JR (1990) J. Bacteriol 172, 273–280 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Zhang J, Dobson CM, Wu X, Lerner-Ellis J, Rosenblatt DS, and Gravel RA (2006) Mol. Genet. Metab 87, 315–322 [DOI] [PubMed] [Google Scholar]
  • 48.Johnson CL, Buszko ML, and Bobik TA (2004) J. Bacteriol 186, 7881–7887 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Reczkowski RS, Taylor JC, and Markham GD (1998) Biochemistry 37, 13499–13506 [DOI] [PubMed] [Google Scholar]
  • 50.Komoto J, Yamada T, Takata Y, Markham GD, and Takusagawa F (2004) Biochemistry 43, 1821–1831 [DOI] [PubMed] [Google Scholar]
  • 51.Suh S-J, and Escalante-Semerena JC (1995) J. Bacteriol 177, 921–925 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Yamanishi M, Labunska T, and Banerjee R (2005) J. Am. Chem. Soc 127, 526–527 [DOI] [PubMed] [Google Scholar]
  • 53.Dobson CM, Wai T, Leclerc D, Kadir H, Narang M, Lerner-Ellis JP, Hudson TJ, Rosenblatt DS, and Gravel RA (2002) Hum. Mol. Genet 11, 3361–3369 [DOI] [PubMed] [Google Scholar]
  • 54.Lerner-Ellis JP, Gradinger AB, Watkins D, Tirone JC, Villeneuve A, Dobson CM, Montpetit A, Lepage P, Gravel RA, and Rosenblatt DS (2006) Mol. Genet. Metab 87, 219–225 [DOI] [PubMed] [Google Scholar]
  • 55.Notredame C, Higgins DG, and Heringa J (2000) J. Mol. Biol 302, 205–217 [DOI] [PubMed] [Google Scholar]
  • 56.Wallace AC, Laskowski RA, and Thornton JM (1995) Protein Eng 8, 127–134 [DOI] [PubMed] [Google Scholar]
  • 57.Baker NA, Sept D, Joseph S, Holst MJ, and McCammon JA (2001) Proc. Natl. Acad. Sci. U. S. A 98, 10037–10041 [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES